MOSAIC: An integrated ultrasonic 2-D array system

An investigation into the development of an ultrasound imaging system capable of customization for multiple applications via the tessellation of in-system programmable scalable modules, or tiles, is presented here. Each tile contains an individual ultrasonic array, operating at +/-3.3V, which can be assembled into a larger ‘mosaic’ of multiple tiles to create arrays of any size or shape. The ability to form an imaging system from generic building blocks which are physically identical for manufacturing purposes yet functionally unique via programming to suit the application has many potential benefits in the field of ultrasonics. The system is primarily targeted at underwater sonar and non-destructive testing, as defined by the current excitation frequency, but the concept is equally applicable to applications in biomedical ultrasound

A modular FPGA-based ultrasonic array system for applications including non-destructive testing

This paper reports work aimed at the development of an ultrasonic imaging system comprising modular, reprogrammable building blocks, or tiles, which can be customised for multiple applications, including and within non-destructive testing (NDT), by the user. The key component is an autonomous module containing the ultrasonic array and all the electronics necessary to operate it. This contrasts with most previous research on system integration which has focused only on the transducer and front-end electronics.<p></p> In the present work, a 4 4 element 2D piezoelectric array with a 16 mm 16 mm aperture has been produced, with the entire transmission and reception electronics within the same footprint. The proximity of the transducer array and electronics removes the need for cabling, reducing signal degradation due to cross talk and interference. In addition, it avoids the problem of electrical impedance matching of cable between the array elements and the electronics. <p></p> Pulse-echo insertion loss of 48 dB has been measured from back-wall reflections in 73 mm-thick aluminium without decoding, and results with decoded signals show adequate signal-to-noise ratio (SNR) with 3.3 V excitation at an operating frequency of 1.2 MHz, within the range required for deep penetration in nuclear power plant. <p></p> Crucially, the ability to construct 2D arrays of any size and shape from generic building blocks represents a departure from almost all previous work in ultrasound, which has traditionally been highly application specific. This may allow ultrasonic NDT to be used in applications for which the investment in customised devices could not previously be justified. <p></p&gt

MOSAIC: A Scalable reconfigurable 2D array system for NDT

This paper documents the development of a scalable 2D array system, or Mosaic that can be targeted at a wide range of NDT applications by way of a reconfigurable tile that can be tessellated to form arrays of any size and shape. Close coupling permits utilization of excitation voltages as low as +/-3.3V with insertion loss of 48dB on reflection from an aluminum back wall at 73mm achieved using 2D arrays without decoding

Microsatellite Markers for Red Drum, Sciaenops ocellatus

Polymerase chain reaction (PCR) primers are reported for 68 nuclear-encoded microsatellites developed during the past several years from genomic libraries of red drum (Sciaenops ocelwtus). All68 microsatellites were tested for reproducibility and polymorphism on a sample of five to 12 red drum; 60 of the microsatellites were found to be polymorphic. Estimates of observed and expected heterozygos- ity (gene diversity) and tests of conformity of genotypes to Hardy-Weinberg equi- librium were carried out for a subset of 31 microsatellites on a larger sample of 45 adults provided by Texas Parks and Wildlife. Levels of allelic and gene diversity were average relative to values observed for marine and anadromous fishes. The set of genetic markers should be useful for a variety of studies, including moni- toring and assessment of red drum stock enhancement

NEDA—NEutron Detector Array

The NEutron Detector Array, NEDA, will form the next generation neutron detection system that has been designed to be operated in conjunction with γ-ray arrays, such as the tracking-array AGATA, to aid nuclear spectroscopy studies. NEDA has been designed to be a versatile device, with high-detection efficiency, excellent neutron-γ discrimination, and high rate capabilities. It will be employed in physics campaigns in order to maximise the scientific output, making use of the different stable and radioactive ion beams available in Europe. The first implementation of the neutron detector array NEDA with AGATA 1π was realised at GANIL. This manuscript reviews the various aspects of NEDA

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

The new neutron multiplicity filter NEDA and its first physics campaign with AGATA

A new neutron multiplicity filter NEDA, after a decade of design, R&D and construction, was employed in its first physics campaign with the AGATA spectrometer. Properties and performance of the array are discussed